|
| Author, journal (year) [Ref] | Country | Age | Sex (M/F) | Number of pts. (case/control) | Study design | Enrollment period | Tumor stage | Specific immunotherapy arm | Control arm | Specific immunotherapy course | Length of follow-up |
|
| Asahara et al., J Transl Med (2013) [8] | Japan | Median (range) 61.3 (33–80) years | 66/46 | 112 (31/81) | Retrospective case-control study | 2009.3–2010.2 | Unknown | KIF20A-66 HLA-A24-restricted peptide + chemotherapy | Chemotherapy | 1.0 or 3.0 mg/body peptide × 8 in a 56 days cycle + 1.0 or 3.0 mg/m2 gemcitabine per 2 weeks | Unknown |
| Bernhardt et al., Br J Cancer (2006) [9] | Norway | Range: 40–72 years | 26/22 | 48 (26/22) | Phase I/II case-control study | 2000.9–2003.3 | Unknown | Telomerase peptide vaccine | Negative peptide | 3 injections in week 1 and 1 weekly injection in weeks 2, 3, 4, 6, and 10 | 10–575 days (survival days from start of treatment) |
| Brett et al., J Clin Oncol (2002) [10] | UK | Median (range) 62.95 (44–79) years | 24/6 | 30 | Phase II self-control study | Unknown | II, III, IV | Anti-gastrin-17 antibody | Unknown | 3 doses of 100 μg or 250 μg of G17DT on weeks 0, 2, and 6 | 16 weeks |
| Cai et al., Chinese Journal of Cancer Biotherapy (2013) [11] | China | Median (range) 64 (30–75) years | 13/11 | 24 | Self-control study | 2011.7–2012.5 | III, IV | DC pulsed with antigens of PANC-1 cells + CIK | Unknown | 1 × 106 DC × 4 + 1 × 106 CIK × 3 | 4 weeks after first treatment to 16.7 months |
| Chawla et al., Mol Ther (2010) [12] | USA | Median (range) 64 (50–83) years | 7/6 | 13 (7/6) | Phase I/II case-control study | 2007.10–2009.1 | Unknown | Positive Rexin-G vaccine | Negative vaccine | 1-2 × 1011 cfu Rexin-G × 12 | 0–12 months |
| Endo et al., J Hepatobiliary Pancreat Sci (2012) [13] | Japan | Mean age 62 ± 8.1 years | 13/11 | 24 (9/15) | Phase I case-control study | 2003.11–2007.7 | IA, IIA, IIB, IV | DC + OK432 | OK432 | 1.0 × 108 DC + 0.1 mL OK432 | 0.7–6.1 years |
| Gjertsen et al., Int J Cancer (2001) [14] | Norway | Range: 35–77 years | 19/18 | 37 (17/20) | Phase I/II case-control study | 1996.11–1998.11 | Unknown | K-ras peptide vaccination + GM-CSF | Negative peptide | 100 μg (single mutant ras peptide or a mixture of 4 mutant ras peptides) × 4 + 40 μg GM-CSF × 4 | 3–6 months after first injection to 2 years |
| Kameshima et al., Cancer Sci (2013) [15] | Japan | Range 50–80 years | 3/3 | 6 | Self-control study | 2005.12–2010.11 | Unknown | Survivin-2B80-88 peptide + IFA + α-interferon | Unknown | (1 mg/1 mL peptide + 1 mL IFA) × 4 + 3,000 IU α-interferon × 12 | Unknown |
| Koido et al., Clin Cancer Res (2014) [16] | Japan | Range 39–73 years | 7/4 | 11 | Phase I self-control study | 2011.8–2013.1 | IV | DC pulsed with multiple WT-1 peptides + chemotherapy | Unknown | 1 × 107 DC/WT-1 cells/dose × 5 + 1000 mg/m2 gemcitabine × 5 | 800 days after first injection |
| Kondo et al., Anticancer Res (2008) [17] | Japan | Range 51–84 years | 14/6 | 20 | Self-control study | 2001–2006 | III, IV | DCs pulsed with MUC1 peptide + CTLs stimulated by MUC1-expressing cells | Unknown | (1.1 × 107 to 3.1 × 108 MUC1-DCs + 5.0 × 108 to 6.8 × 109) × 2 to 15 times | Unknown |
| Kubuschok et al., Hum Gene Ther (2012) [18] | Germany | Range 48–66 years | 4/3 | 7 | Self-control study | 1997–2000 | II, III | muRas-LCL | Unknown | 5 × 106 muRas-LCL × 8 | 7–52 weeks |
| Le et al., J Immunother (2013) [19] | USA | Median (range) 62 (44–77) years | 21/9 | 30 (15/15) | Phase Ib, randomized study | 2009.3–2010.12 | II, III, IV | Ipilimumab + GVAX | Ipilimumab | 10 mg/kg ipilimumab + 2.5 × 108 cells of GVAX | 0–30 months |
| Le et al., J Clin Oncol (2015) [20] | USA | Median (range) 63 (45–87) years | 53/37 | 90 (61/29) | Multicenter, randomized, case-control phase II trial | 2011.9–2012-11 | Unknown | Cy/GVAX plus CRS-207 | Cy/GVAX | (200 mg/m2 cy + 2.5 × 108 cells GVAX) × 6 + 1 × 109 colony-forming units CRS-207 × 6 | 600 days after first treatment |
| Liu, Chin J Clinicians (2012) [21] | China | Median (range) 61 (42–76) years | 27/23 | 50 (25/25) | Randomized, case-control study | 2010.6–2011.12 | I, II, III, IV | DC pulsed with tumor cells lysates + CIK + chemotherapy | Chemotherapy | 2 × 109 DC-CIK cells × 6 + 600 mg/m2 5-FU | Unknown |
| Liu et al., Nanjing yi ke da xue xue bao (2010) [22] | China | Range 48–79 years | 17/13 | 30 (15/15) | Randomized, case-control study | Unknown | III, IV | DC pulsed with tumor cells lysates + CIK + chemotherapy | Chemotherapy | DC × 4 + 1 g/m2 chemotherapy × 18 | 7 days after therapy |
| Middleton et al., Lancet Oncol (2014) [23] | UK | Range 55–69 years | 608/454 | 1062 (704/358) | Multicenter, open-label, phase III randomized control trial | 2007.3–2011.3 | Unknown | Telomerase peptide vaccine GV1001 + gemcitabine and capecitabine | Gemcitabine, capecitabine | 1000 mg/m2 gemcitabine × 6 + 830 mg/m2 capecitabine × 2 + GV1001 | Followed up for a median of 6.0 months |
| Nishida et al., J Immunother (2014) [24] | Japan | Median (range) 60 (41–75) years | 17/15 | 32 | Phase I self-control study | 2008–2010 | Unknown | WT-1 peptides vaccine + gemcitabine | Unknown | 1000 mg/m2 gemcitabine × 6 + 0.3 to 3.0 mg WT-1 vaccine × 4 | 30 months |
| Picozzi et al., Eur J Cancer (2015) [25] | USA | Range 39–80 years | 33/25 | 58 (29/29) | Phase Ib case-control study | 2102.6–2013.2 | Unknown | 90Y-clivatuzumab tetraxetan (anti-MUC5ac monoclonal antibody) + gemcitabine | 90Y-clivatuzumab tetraxetan | 6.5 mCi/m2 Y-clivatuzumab tetraxetan × 3 ± 200 mg/m2 gemcitabine × 4 | 12 months after first injection |
| Qiu et al., Int J Clin Oncol (2013) [26] | China | Mean (range) age 60.1 ± 8.4 (44–90) years | 12/2 | 14 | Phase I self-control study | 2004.3–2009.2 | III, IV | DC pulsed with α-Gal expressing cancer cell lysate + CIK | Unknown | (2 × 109 cells–10 × 109 cells) (DCs + CIKs)/injection × 1–5 times | 24 months after first injection |
| Sultana et al., BMC Cancer (2009) [27] | UK | Median (range) 60 (47–67) years | Unknown | 19 | Randomized phase II self-control trial | 2003.2–2005.7 | IVa, IVb | Anti-carcinoembryonic antigen I131KAb201 antibodies | Unknown | 50 mCi–75 mCi KAb 201 via either the intra-arterial or intravenous delivery route | 90 days posttreatment |
| Suzuki et al., J Immunother (2014) [28] | Japan | Median (range) 62 (48–74) years | 4/5 | 9 | Nonrandomized, open-label, phase I self-control study | Unknown | III, IV | KIF20A-10-66 peptide + gemcitabine | Unknown | 0.5–3 mg/body KIF20A-10-66 peptide × 4 + 1000 mg/m2 gemcitabine × 3 | 94–366 days |
| Wen et al., Xiandai zhongxiyi jiehe zazhi (2013) [29] | China | Range 49–78 years | 33/27 | 60 (30/30) | Randomized, case-control study | 2008.3–2011.3 | Unknown | DC pulsed with tumor cells lysates + CIK + chemotherapy | Chemotherapy | 2 × 109 DC-CIK cells × 6 + 600 mg/m2 5-FU | 2–26 months |
| Yanagimoto et al., Oncol Rep (2010) [30] | Japan | Median (range) 64 (48–80) years | 13/8 | 21 | Nonrandomized, open-label, phase II self-control study | 2006.9–2008.3 | IVa, IVb | PPV + gemcitabine | Unknown | 3 mg/peptide were administered weekly + 1000 mg/m2 gemcitabine per week for 3 weeks | 3–24 months |
| Yutani et al., Oncol Rep (2013) [31] | Japan | Median (range) 61 (44–78) years | 27/14 | 41 | Open-label phase II self-control study | 2008.11–2011.3 | IVa, IVb | PPV | Unknown | 4 peptides (3 mg/each peptide) administered once a week for 6 consecutive weeks | Over 800 days |
| Zhang, Zhongguo xian dai yi xue za zhi (2014) [32] | China | Mean range 58.2 ± 5.2 (48–78) years | 33/27 | 60 (30/30) | Randomized, case-control study | 2010.1–2012.6 | I, II, III, IV | DC pulsed with tumor cells lysates + CIK + chemotherapy | Chemotherapy | 2 × 109 DC-CIK cells × 4 + 15 mg/kg 5-FU × 4 | Over 3 years |
|
